C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

C4 Therapeutics, Inc.NASDAQ: CCCC

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns positive

Q1 FY2026 financing cash flow was $462K, compared with -$46K a year earlier. Trailing-twelve-month financing cash flow was $126.91M. Over 3 fiscal years it compounded at +379.4% a year.

Context

  • Financing cash flow amounted to 351.6% of revenue in FY2025, up 224.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near $462K or moves back toward the trailing-twelve-month quarterly average of $31.73M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$462K-99.6% QoQ
Last fiscal yearDec 2025
$126.4M+178.8% YoY
LTMMar 2026
$126.91M+1085.3% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1104.3%——
1 year+178.8%——
3-year CAGR+379.4%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
126.4M USD
Year-over-year change
+178.8%
4-year CAGR
-7.3%

Financing Cash Flow vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1085.3% is the 3rd highest of 9, against a peer median of +86.3%.
  • Financing cash flow amounts to 364.0% of revenue for CCCC, versus a peer median of 404.2%.
CCCC Competitors
Financing Cash Flow for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$180.48M USD+300903.0%+202.6%10116.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$126.91M USD+1085.3%+379.4%364.0%
PEPGPepGen Inc.LTM Mar 2026$109.5M USD+6044.6%-1.3%—
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$89.31M USD+520.7%-5.8%258.5%
OABIOmniAb, Inc.LTM Mar 2026$27.87M USD+110.1%-36.8%96.4%
CDXSCodexis, Inc.LTM Mar 2026$26.83M USD-17.0%—34.4%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$24.21M USD-50.6%-7.8%1242.3%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$16.27M USD+62.5%-16.5%549.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.3M CHF-109.0%-9.9%—
Peer median (excluding CCCC) —+86.3%-7.8%404.2%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.